Truss M C, Becker A J, Thon W F, Kuczyk M, Djamilian M H, Stief C G, Jonas U
Department of Urology, Medizinische Hochschule Hannover, FRG.
Eur Urol. 1994;26(1):40-5. doi: 10.1159/000475340.
The implantation of a penile prosthesis is still the ultima ratio for patients with erectile dysfunction who fail other treatment options such as pharmacotherapy and penile venous surgery. Despite mostly favorable results regarding restoration of erectile capacity, penile allografts are often not accepted for various reasons. Therefore, pharmacotesting with a mixture of calcitonin gene-related peptide and prostaglandin E1 (CGRP/PGE1) was offered to different selected patients populations: 28 patients with erectile dysfunction and venous leakage who failed penile venous surgery, 28 patients with erectile dysfunction and venous leakage (who refused penile venous surgery) and 12 patients without venous leakage, but poor response to maximum doses of papaverine/phentolamine, received 5 micrograms CGRP plus 10 micrograms PGE1. Erections sufficient for intercourse were noted in 19/28 (67.9%), 20/28 (71.4%) and 11/12 (91.7%) patients, respectively. Our data show that a combination of CGRP and PGE1 may be an alternative to penile implants in selected patients.
对于那些其他治疗方法(如药物治疗和阴茎静脉手术)失败的勃起功能障碍患者,阴茎假体植入仍是最终手段。尽管阴茎假体植入在恢复勃起功能方面大多能取得良好效果,但由于各种原因,阴茎异体移植往往不被接受。因此,我们对不同的特定患者群体进行了降钙素基因相关肽与前列腺素E1(CGRP/PGE1)混合物的药物测试:28例阴茎静脉手术失败且伴有勃起功能障碍和静脉漏的患者、28例伴有勃起功能障碍和静脉漏(拒绝阴茎静脉手术)的患者以及12例无静脉漏但对最大剂量罂粟碱/酚妥拉明反应不佳的患者,均接受了5微克CGRP加10微克PGE1的治疗。分别有19/28(67.9%)、20/28(71.4%)和11/12(91.7%)的患者出现了足以进行性交的勃起。我们的数据表明,对于特定患者,CGRP和PGE1联合使用可能是阴茎植入的一种替代方法。